Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab effectiveness and PROs in RMS patients transitioning from fumarates or fingolimod
2023-507493-41-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, open-label, single-arm trial of ofatumumab in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Novartis. Primary endpoint: Annual relapse rate over 96 weeks. Started Jul 2024; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2023-507493-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507493-41-00.